AlphaGene Inc., of Woburn, Mass., added Raul Krauss and Kulvinder Saini to its neurobiology discovery research team.

Amgen Inc., of Thousand Oaks, Calif., added Paul Reason to its board.

Arrow Therapeutics Ltd., of London, appointed Piers Morgan finance director.

Axys Pharmaceuticals Inc., of South San Francisco, named Daniel Makover vice president, business development.

Cellegy Pharmaceuticals Inc., of South San Francisco, appointed Julian Baker to its board.

Corvas International Inc., of San Diego, promoted George Vlasuk to chief scientific officer, Carolyn Felzer to vice president and controller, and Edwin Madison to vice president of biological research.

Cyanotech Corp., of Kailua-Kona, Hawaii, named David Rosenthal to its board of directors and audit committee.

Diversa Corp., of San Diego, appointed Mark Burk vice president, chemical product development and Juan Estruch senior director, business development; and promoted Dan Robertson to senior director, enzyme technology.

Elan Pharmaceuticals plc, of Dublin, Ireland, appointed Christopher O'Brien as vice president, medical affairs of Elan Pharmaceuticals, North America.

Exact Sciences Corp., of Maynard, Mass., added Jeffrey Walsh as vice president of business development.

Gemini Genomics plc, of Cambridge, UK, added Steven Butcher as vice president, science and Anders Berkenstam as director of science at Gemini Genomics AB.

GLYCODesign Inc., of Toronto, named Richard Schabas vice president, corporate development.

Matrix Pharmaceuticals Inc., of Fremont, Calif., appointed Eric Brandt to its board.

MedImmune Inc., of Gaithersburg, Md., promoted James Young to president, research and development, and Michael Richman to senior vice president, corporate development and administration.

Nabi, of Boca Raton, Fla., added Geoffrey Cox, CEO and chairman of Aronex Pharmaceuticals Inc., to its board.

Physiome Sciences Inc., of Princeton, N.J., appointed Charles DeLisi to its scientific advisory board.

StemCells Inc., of Sunnyvale, Calif., added Roger Perlmutter to its board of directors.

Stressgen Biotechnologies Corp., of Victoria, British Columbia, named Peter Zarevics director of clinical operations; Lee Mizzen vice president, scientific affairs; Heather Boux director of research in its biochemical division; and Andrea Scott director of finance/controller.

Transgenomic Inc., of Omaha, Neb., added Leslie Beadling as vice president of market development, biopharmaceuticals.

Tripos Inc., of St. Louis, appointed Douglas Danne senior vice president of sales.

Vertex Pharmaceuticals Inc., of Cambridge, Mass., promoted John Alam to senior vice president, drug evaluation and approval and Jeff Wilson to vice president, pharmaceutical operations.

ViroLogic Inc., of South San Francisco, appointed David Persing to its board.

V.I. Technologies Inc., of Watertown, Mass., added James Hope as vice president of molecular sciences.

Zycos Inc., of Lexington, Mass., named William Knight chief financial officer.

Zyomyx Inc., of Hayward, Calif., appointed Frances Heller vice president, intellectual property and legal affairs.